Taiwan has become the latest APAC region to approve the use of 2’-fucosyllactose (2’-FL) – a human milk oligosaccharide (HMO) – in nutrition products for infant and young children, with firms hopeful of further sector growth as more authorities permit the use of the ingredient.
You May Also Like

Global conference on infant nutrition in Wellington
INCOctober 17, 2022

US formula shortage: FDA refutes claims of postponing all applications under discretion policy
INCAugust 30, 2022

‘Possible opportunity’: ANZ infant nutrition firms gear up for US market entry amid formula shortage
INCJune 27, 2022